Hexamer Therapeutics, Inc
StreetZero Signal 70
About Hexamer Therapeutics, Inc
Hexamer Therapeutics, Inc. is a biotechnology company focused on next-generation vaccine technology. It received USAMRDC funding to develop breakthrough vaccine technology for global health security. The company is headquartered in Pullman, WA.
LATEST FUNDINGPrivate Placement
$500K
Announced 2026-09-15
TOTAL RAISED$500,000
IN THE NEWS
- 🔗 Hexamer Therapeutics | MTEC
- 🔗 Hexamer Therapeutics: Next-Generation Vaccine Technology
- 🔗 Hexagon Bio Closes $47 Million in Series A Financing to Advance Novel Oncology and Infectious Disease Therapies - Hexagon
- 🔗 Robert Bogden
- 🔗 FoRx Therapeutics AG Raises EUR 10 Million Seed Round First Company to Develop a Pipeline of Drugs Targeting DNA Replication Stress for Cancer - FoRx Therapeutics
EMPLOYEES—
FOUNDED—
HQPullman, WA, United States
Industry
Biotechnology
Tags
BiotechnologyVaccine TechnologyPrivate Placement
Investors
Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.
Key highlights
- Raised $500,000 in private placement funding.
- Secured USAMRDC support for vaccine technology development.
- Focuses on breakthrough vaccines for global health security.
- Based in Pullman, Washington.
Ask StreetZero about Hexamer Therapeutics, Inc
Put our AI to work on this deal.
Similar companies
Other Biotechnology deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account